

I. CURRICULUM VITAE

NAME: Wayne R. Snodgrass, M.D., Ph.D. Date: July 2003

PRESENT POSITION: Professor, Pediatrics and Pharmacology-Toxicology
Head, Clinical Pharmacology-Toxicology Unit
Medical Director, Texas Poison Center
University of Texas Medical Branch
301 University Blvd
Galveston, TX 77555--0631

BIOGRAPHICAL:

EDUCATION:

- | | | |
|------|--------------|------------------------------------|
| 1968 | Chemistry | B.S. Butler University, Indpls, IN |
| 1971 | Pharmacology | M.S. Indiana University |
| 1972 | Medicine | M.D. Indiana University |
| 1976 | Pharmacology | Ph.D. Indiana University |
- 1972—1973 Research Associate, Dept of Pharmacology-Toxicology
Indiana University, Bloomington, IN
Private Practice, Pediatrics, part-time
- 1973—1976 Research Associate and Staff Fellow in
Clinical Pharmacology
Laboratory of Chemical Pharmacology and
Hypertension and Endocrine Branch
National Heart, Lung and Blood Institute
N.I.H. (National Institutes of Health)
Bethesda, MD
- 1976—1979 Pediatric Resident, Dept of Pediatrics
University of Colorado Health Sciences Center
Denver, CO
- 1979—1980 Fellow and Instructor
Clinical Pharmacology and Medical Toxicology
Division of Clinical Pharmacology-Toxicology and
Rocky Mountain Poison Center
University of Colorado Health Sciences Center
Denver CO

PROFESSIONAL AND TEACHING EXPERIENCE:

1980—1984 Assistant Professor, Depts. of Pediatrics and Pharmacology-Toxicology
University of Kansas Medical Center

1984—1991 Associate Professor, Depts. of Pediatrics and Pharmacology-Toxicology
University of Texas Medical Branch

1991-- Professor, Pediatrics
1995-- Professor, Pharmacology-Toxicology
University of Texas Medical Branch

RESEARCH ACTIVITIES:

1. Phenytoin NIH-BRSG-1561-19 2/1/81 to 3/31-82
 Terato- \$6,800
 Genicity
2. Pediatric McNeil Pharmaceutical 10/1/81 to 6/30/84
 Clinical
 Pharmacology
 of Acetaminophen
3. Pediatric private gift 7/1/81 to 6/30/83
 Clinical
 Pharmacology of
 6-Mercaptopurine
4. Perfluoro- U.S. Army 10/1/82 to 9/30/83
 chemical \$11,000
 Blood Substitute
 Effect on Drug
 Pharmacokinetics
5. Mid-America Kansas Legislature 7/1/82
 Regional —————
 Poison Center annual thereafter
6. Regional McNeil Pharmaceutical 7/1/83 to 6/30/85
 Poison —————
 Center
 Expansion Project
7. Furosemide American Heart Assoc 7/1/83 to 6/30/84
 Biotrans- AHA-KS 83-83
 transformation
 in Premature Infants
8. Nucleophile NIH-UTMB Intramural 4/1/85 to 3/31/86
 Blockade of Research Grant, \$5,700
 Phenytoin
 Teratogenicity

9. Developmental Grant for a Clinical Pharmacology Unit Pharmaceutical Manufacturers Association Foundation, — 7/1/85 to 6/30/88

10. Metabolic Profiling of 6-MP in Childhood Leukemia to Improve Patient Outcome NIH-UTMB Cancer Center Support Grant CA 17701 \$8,000 7/1/86 to 5/31/87

11. Treatment Protocols for Potentially Toxic Chemicals on the Space Shuttle NASA \$30,000 7/1/87 to 6/30/88

12. Clinical Pharmacology Fellowship Award Pharmaceutical Manufacturers Association Foundation, — 7/1/87 to 12/31/88

13. Flumazenil, A Benzodiazepine Antagonist Hoffman-La Roche, Inc. Co-Investigator, — 7/1/87 to 6/30/90

14. Use of Gastrointestinal Dialysis to Enhance Removal of Environmental/Occupational Chemicals from Deep Compartment Body Storage Sites Unfunded

15. Urinary Thioether Excretion As An Index Of Exposure to Environmental Chemicals Agency for Toxic Substances and Disease Registry (ATSDR), Clinical Fellowship in Environmental Medicine 9/1/93 to 8/31/95

16. Texas State Poison Center System Texas Legislature Sept 1994 forward annually
Federal Gov't supplement \$250,000 annually

17. Pesticides in Children EPA (Environmental Protection Agency) pending review \$1.3 million

18. Clinical Investigator Research Education Award National Institutes of Health K-30 grant, \$1,000,000, 1999—2004 a sub-investigator

COMMITTEE RESPONSIBILITIES:

A. National

1. American Academy of Pediatrics,
Committee on Drugs, 1984 -- 1991
2. United States Pharmacopoeia (USP)
Pediatric Advisory Committee, 1990 to present
3. American Society for Clinical Pharmacology and Therapeutics
Admissions Committee, 1986—1989
4. American Academy of Clinical Toxicology
Board of Trustees, 1987 -- 1996
5. American Academy of Pediatrics
Executive Committee
Section on Clinical Pharmacology, 1992 to present
6. American Board of Medical Toxicology
Board of Examiners, 1986 -- 1990
7. Environmental Protection Agency (EPA)
Ad Hoc Committee on Pesticide Exposure, 1990—1991
8. Environmental Protection Agency (EPA)
Blue Ribbon Panel, Evaluation of Chlorpyrifos, 1998
9. Chair, Poison Center Coordinating Committee
State of Texas, 1994—1998
10. President, American Academy of Clinical Toxicology, 1992—1994
11. American College of Medical Toxicology
National Panel
Review of Consensus Guidelines for Antidotes to be Stocked by Hospitals, 1999
12. Chair, Pediatrics Advisory Panel
United States Pharmacopoeia (USP), 2000 to 2005
13. American Association of Poison Control Centers, Committee on National
Management Protocol Guidelines, 1999 to present
14. Poison Center Coordinating Committee member, State of Texas, 1994—present
15. American Association of Poison Control Centers, Scientific Review Committee, 2000-2005

B. University of Texas Medical Branch

1. Pharmacy and Therapeutics Committee
University Hospital, 1985 to present
2. Graduate Student Admission Committee
Department of Pharmacology-Toxicology, 1984—1999
3. Library Committee
Department of Pediatrics, 1985—1994
4. Executive Council
Department of Pediatrics, 1989—1992
5. Research Committee
Department of Pediatrics, 1987—1994
6. Ad Hoc Committee on Occupational Medicine and
Occupational Toxicology, 1991—present
7. National Student Research Forum
abstract reviewer, 1986 to present
8. Environmental Health Program
Ad Hoc Task Force, 1999—2000
9. Alternative Medicine Committee, 1999—2002
10. PhD thesis committee for graduate students in
Pharmacology and Toxicology
11. Clinical Research Education Office (CREO)

Steering Committee, 1999--2004

TEACHING RESPONSIBILITIES AT UTMB:

1. Clinical Pharmacology-Toxicology: Drug Use in Clinical Practice, 4th Year Senior Medical Student Course, one month each year, 40 lectures/sessions, clinical cases, therapeutic concepts
2. Medical Pharmacology, Integrated Curriculum small group sessions, clinical cases
3. Co-director, graduate school course BBSC 6108 Basic Biomedical Science Curriculum module 1B Principles of Molecular Pharmacology sessions on Pharmacokinetics and Biotransformation
4. Introduction to Research Department of Pharmacology-Toxicology
5. Environmental Human Toxicology Department of Preventive Medicine and Community Health
6. Physician Housestaff Core Lecture Series Management of Poisoning and Overdose, Clinical Pharmacokinetics
7. Grand Rounds, Pediatrics and Internal Medicine
8. Poison Center Case Conference Teaching sessions
9. Clinical Pharmacology-Toxicology Teaching Rounds
10. Clinical Pharmacology-Toxicology Consultation Service Elective for Housestaff and Medical Students
11. Medical Toxicology Practicum offered nationally to candidates for the American Board of Medical Toxicology
12. Annual Texas Pediatric CME (Continuing Medical Education) Conference
13. Supervision of Pediatric Housestaff Grand Rounds presentations
14. Pediatric Housestaff Journal Club
15. Pediatric Teaching Rounds Driscoll Children's Hospital, Corpus Christi TX
16. Pediatric Advanced Life Support course instructor
17. Drug Interactions of Antibiotics Infectious Disease Fellows and Staff, Internal Medicine
18. General Clinical Research Center course for physicians and scientists Pharmacokinetics in Clinical Research
19. Mentor program for Medical Students, UTMB
20. Mentor, Pediatric Resident Research Project

CLINICAL RESPONSIBILITIES:

1. Attending Physician, Pediatric Intensive Care Unit (PICU) 2—4 months per year, and Infant Special Care Unit (ISCU) (level II—iii) one month per year, 1980—1992
2. Medical Director, Texas State Poison Center—Houston/Galveston
3. Physician, Clinical Pharmacology-Toxicology Consulting Service UTMB
4. Consulting Physician and final decision maker for evening, night and weekend Drug Assays and Drug Screens, University Hospital emergency department and Department of Pathology

REVIEWER FOR JOURNALS:

1. New England Journal of Medicine
2. Journal of Pediatrics
3. Pediatrics
4. Drug Metabolism and Disposition
5. Toxicology and Applied Pharmacology
6. Journal of Toxicology Clinical Toxicology
7. Neonatal Pharmacology Quarterly
8. Editorial Board, Poisindex Computer Information System, 1990 to present
9. Editorial Advisory Board
Pediatric Primary Care
10. Invited Reviewer by Environmental Protection Agency (EPA)
textbook: Recognition and Management of Pesticide Poisoning





MEMBERSHIP IN SCIENTIFIC SOCIETIES:

1. American Society for Clinical Pharmacology and Therapeutics
2. American College of Clinical Pharmacology
3. American Academy of Clinical Toxicology
4. American College of Medical Toxicology
5. American Academy of Pediatrics
6. International Society for the Study of Xenobiotics

BOARD CERTIFICATION:

- | | |
|------|---|
| 1980 | American Board of Pediatrics |
| 1981 | American Board of Medical Toxicology |
| 1982 | American Board of Toxicology (Basic Sciences) |
| 1991 | American Board of Clinical Pharmacology |

MEDICAL LICENSE INFORMATION:

- | | |
|----------|---|
| Colorado |  |
| Indiana |  |
| Kansas |  |
| Texas |  |

HONORS:

- 1981 Outstanding Teacher Award
Department of Pediatrics
University of Kansas Medical Center
- 1983 American Academy of Clinical Toxicology
Research Fellowship Award
- 1985 American Academy of Clinical Toxicology
Research Fellowship Award
- 1987 Elected a Fellow of the
American Academy of Clinical Toxicology
- 1988 Golden Rattle Award, outstanding teacher
Department of Pediatrics
University of Texas Medical Branch
- 1999 Elected Chairperson
Pediatrics Advisory Panel
United States Pharmacopoeia (USP)

Ph.D. THESIS:

Placental Transfer of Drugs (Master's)

Probable Mechanism of Isoniazid-Related Hepatic Injury (Ph.D.)

**APPEARS THIS WAY
ON ORIGINAL**

BIBLIOGRAPHY

A. ARTICLES IN JOURNALS

1. Miller FP, Cox RH, Snodgrass WR and Maicker RP: Comparative effects of p-chlorophenylalanine, p-chloro-amphetamine and p-chloro-N-methylamphetamine on rat brain norepinephrine, serotonin and 5-hydroxyindole-3-acetic acid. *Biochem Pharmacol* 1970;19:435—442
2. Maickel RP and Snodgrass WR: Physicochemical factors in maternal-fetal distribution of drugs. *Toxicol Appl Pharmacol* 1973;26:218-230
3. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow DJ and Keiser HR: Increased incidence of isoniazid hepatitis in rapid acetylators and possible explanation by analysis of urinary metabolites of isoniazid. *Clin Pharmacol Therap* 1975;18:70—79
4. Mitchell JR, Snodgrass WR and Gillette JR: The role of biotransformation in chemical-induced liver injury. *Environ Health Perspect* 1976;15:27—38
5. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR and Nelson SD: Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. *Annals Intern Med* 1976;84:181—192
6. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR and Corcoran GB: Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. *Science* 1976;193:901—903
7. Taylor AA, Mitchell JR, Bartter FC, Snodgrass WR, McMurtry RJ, Gill JR and Franklin RB: Effect of aminogluthethimide on blood pressure and steroid secretion in patients with low renin essential hypertension. *J Clin Invest* 1978;62:162—168
8. Nelson SD, Mitchell JR, Snodgrass WR and Timbrell JA: Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. *J Pharmacol Exper Therap* 1978;206:574—585
9. McMurtry RJ, Snodgrass WR and Mitchell JR: Renal necrosis, glutathione depletion and covalent binding after acetaminophen. *Toxicol Appl Pharmacol* 1978;46:87—100
10. Maickel RP, Bowman DR, Fedynskyj N, Snodgrass WR and Ryan MP: Iproniazid-induced biochemical changes in mice. *Res Commun Chem Pathol Pharmacol* 1979;25:131—141
11. Timbrell JA, Mitchell JR, Snodgrass WR and Nelson SD: Isoniazid hepatotoxicity: the relationship between covalent binding and metabolism in vivo. *J Pharmacol Exper Therap* 1980;213:364—369
12. Snodgrass WR, Sawyer D, Connor C, Rumack B, Peterson R and Sullivan J: Asymptomatic theophylline overdose. *Drug Intell Clin Pharm* 1980;14:783—784

13. Snodgrass WR, Rumack BH, Sullivan JB, Peterson RG, Cotton EK and Sokol RJ: Selenium childhood poisoning and cystic fibrosis. *Clin Toxicol* 1981;18:211—220
14. Snodgrass WR, Sullivan JB, Rumack BH and Hashimoto C: Mercury poisoning from home gold ore processing. *J Amer Med Assoc* 1981;246:1929—1931
15. Snodgrass WR and Whitfield S: Phenytoin liver glutathione depletion: a possible mechanism of injury. *Veterin Human Toxicol* 1981;23:5—7
16. Snodgrass WR and Doull J: Early aggressive activated charcoal treatment of elemental yellow phosphorus poisoning. *Veterin Human Toxicol* 1982;23:96—98
17. Maickel RP, Seeger J and Snodgrass WR: Physiological disposition of iproniazid in mice. *Acta Pharmacol Sinica* 1983;4:57—60
18. King CR, Mattioli L, Goertz KK and Snodgrass WR: Successful treatment of fetal supraventricular tachycardia with maternal digoxin therapy. *Chest* 1984;85:573—575
19. Kemner JM, Snodgrass WR, Worley SE, Hodges GR, Clark GM and Hignite CE: Interaction of oxygen-carrying resuscitation fluids with morphine. *J Lab Clin Med* 1984;104:433—444
20. Kemner JM, Snodgrass WR, Worley SE, Hodges GR, Melethil S, Hignite CE and Tschanz C: Effect of oxygen-carrying resuscitation fluids on the pharmacokinetics of antipyrine, diazepam, penicillin and sulfamethazine in rats. *Res Commun Chem Pathol Pharmacol* 1984;46:381—400
21. Smith SD, Trueworthy RC, Klopovich PM, Vats TS and Snodgrass WR: Management of Children with isolated testicular leukemia. *Cancer* 1984;54:2854—2858
22. Snodgrass WR: Salicylate toxicity. *Pediatr Clin North Amer* 1986;33:181—191
23. Roy D and Snodgrass WR: Phenytoin metabolic activation: role of cytochrome P450, glutathione, age and gender in rats and mice. *Res Commun Chem Pathol Pharmacol* 1988;59:173—190
24. Machado B, Cross K and Snodgrass WR: Accidental hydrocarbon ingestion cases telephoned to a regional poison center. *Annals Emerg Med* 1988;17:804—807
25. Douidar SM, Richardson CJ and Snodgrass WR: Role of indomethacin in ductus closure: an update evaluation. *Develop Pharmacol Therap* 1988;11:196—212
26. Roberts RJ, Kauffman RE, Mirkin BL, Rumack BH, Snodgrass WR and Spielberg SP: Emergency drug doses for infants and children. *Pediatrics* 1988;81:462—465

27. Roy D and Snodgrass WR: Isocratic separation of phenytoin metabolites by high performance liquid chromatography from human and animal microsomes and urine.
Therap Drug Monit 1989;11:57—62
28. Roberts RJ, Blumer JL, Kauffman RE, Lambert GH, Rumack BH and Snodgrass WR:
SI units.
Pediatrics 1989;83:129—131
29. Snodgrass WR and Dodge WF: Lytic/dpt cocktail: time for rational and safe alternatives.
Pediatr Clin North Amer 1989;36:1285—1291
30. Klein GL, Snodgrass WR, Griffin MP, Miller NL and Alfrey AC: Hypocalcemia complicating Deferoxamine therapy in an infant with parenteral nutrition-associated aluminum overload: evidence for a role of aluminum in the bone disease of infants.
J Pediatr Gastroenterol Nutr 1989;9:400—403
31. Douidar SM and Snodgrass WR: Potential role of fluoroquinolones in pediatric infections.
Rev Infect Dis 1989;11:878—889
32. Snodgrass WR: Antipyresis: how about ibuprofen?
Pediatr Therap Toxicol 1989;3:47—48
33. Roy D and Snodgrass WR: Covalent binding of phenytoin to protein and modulation of phenytoin metabolism by thiols in A/J mouse liver microsomes.
J Pharmacol Exper Therap 1990;252:895—900
34. Winter ML, Ellis MD and Snodgrass WR: Urine fluorescence using a Wood's lamp to detect the antifreeze additive sodium fluorescein: a qualitative adjunct test in suspected ethylene glycol ingestions.
Ann Emerg Med 1990;19:663—667
35. Snodgrass WR: Selected aspects of pediatric intensive care unit clinical pharmacology.
Current Opinion Pediatr 1991;3:314—318
36. Dodge WF, Jelliffe RW, Richardson CJ, McCleery RA, Hokanson JA and Snodgrass WR: Gentamicin population pharmacokinetic model for low birth weight infants using a new nonparametric method.
Clin Pharmacol Therap 1991;50:25—31
37. Snodgrass WR: Ibuprofen usage in antipyresis.
Pediatr Therap Toxicol 1991;5:41
38. Dodge WF, Jelliffe RW, Richardson CJ, Bellanger RA, Hokanson JA and Snodgrass WR: Population pharmacokinetic models. Measures of central tendency.
Drug Invest 1993;5:206—211
39. Dayal HH, Li YH, Dayal V, Mittal CK and Snodgrass WR: Use of medication data to validate an association in community-based symptom prevalence studies.
Arch Environ Health 1994;49:93—97
40. Dodge WR, Jelliffe RW, Zwischenberger JB, Bellanger RA, Hokanson JA and Snodgrass WR: Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation.
Therap Drug Monit 1994;16:552—559

41. Rosen PB, Snodgrass WR and Riggs M: Dietary effect on urinary thioethers. *Arch Environ Health* 1999;54:425--429
42. Albers JW, Cole P, Greenberg RS, Mendel JS, Monson RR, Ross JH, Snodgrass WR, Spurgeon A, and van Gemert M: Analysis of chlorpyrifos exposure and human health: expert panel report. *J Toxicol Environ Health* 1999;2:301--324
43. Dart RC, Goldfrank LR, Chyka PA, Lotzer D, Woolf AD, McNally J, Snodgrass WR, Olson KR, Scharman E, Geller RJ, Spyker D, Kraft M and Lipsy R: Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. *Annals Emerg Med* 2000;36:126--132
44. Snodgrass WR: Herbal products: risks and benefits of use in children. *Curr Therap Res* 2001;62:724--737

B. OTHER

1. Maickel RP, Cox RH, Skir CJ, Snodgrass WR and Miller RP: Some aspects of the behavioral Pharmacology of the amphetamines.
In: AMPHETAMINES AND RELATED COMPOUNDS, Costa E and Garrattini S, eds, Raven Press, NY 1970:72--86
2. Maickel RP, Snodgrass WR and Kuntzman R: Radioactive techniques: the use of labeled drugs.
In: CONCEPTS IN BIOCHEMICAL PHARMACOLOGY, Handbook of Experimental Pharmacology, Brodie BB and Gillette JR, eds, Springer-Verlag, NY 1971;27(2):42--57
3. Maickel RP, Braunstein MC, McGlynn M, Snodgrass WR and Webb RQ: Behavioral, biochemical and pharmacological effects of chronic dosage of phenothiazine tranquilizers in rats.
In: PHENOTHIAZINES AND STRUCTURALLY RELATED DRUGS, Advances Biochem Psychopharmacol, Raven Press, NY 1974;9:593--602
4. Mitchell JR, Potter WZ, Hinson JA, Snodgrass WR, Timbrell JA and Gillette JR: Toxic drug Reactions.
In: CONCEPTS IN BIOCHEMICAL PHARMACOLOGY, Handbook of Experimental Pharmacology, Gillette JR and Mitchell JR, eds, Springer-Verlag, 1975;28(3):383--419
5. Nelson SD, Snodgrass WR and Mitchell JR: Chemical reaction mechanisms responsible for the Tissue injury caused by monosubstituted hydrazines and their hydrazide drug precursors.
In: IN VITRO METABOLIC ACTIVATION IN MUTAGENESIS TESTING, DeSerres FJ, ed, Elsevier, Amsterdam, 1976:257--276
6. Mitchell JR, Nelson SD, Snodgrass WR and Timbrell JA: Metabolic activation of hydrazines to Highly reactive hepatotoxic intermediates.
In: BIOLOGICAL REACTIVE INTERMEDIATES: FORMATION, TOXICITY AND INACTIVATION, Jollow DJ et al, eds, Plenum Press, NY, 1977:271--277
7. Snodgrass WR and Whitfield S: Furosemide biotransformation in a premature infant: urinary excretion of furosemide and its glucuronide metabolite.
In: PROCEEDINGS OF THE FIRST INTERNATIONAL SYMPOSIUM OF DEVELOPMENTAL PHARMACOLOGY, Alan R. Liss, NY, 1983:413--416
8. Mozsik G and Snodgrass WR: Clinical gastrointestinal toxicology.
In: GASTROINTESTINAL TOXICOLOGY, Rozman K and Hanninen O, eds, Elsevier Science Publishers, 1986:436--463

9. Snodgrass WR: Diagnosis and management of chronic pesticide poisoning.
In: CLINICAL MANAGEMENT OF POISONING AND OVERDOSE, Haddad LM and Winchester JF, eds, WB Saunders, Philadelphia PA, 1990:542—551
10. Snodgrass WR: Air pollution: air quality index and ozone.
In: CLINICAL MANAGEMENT OF POISONING AND OVERDOSE, Haddad LM and Winchester JF, eds, WB Saunders, Philadelphia PA, 1990:1131—1138
11. Snodgrass WR and Dodge WF: Peri-operative pharmacologic intervention in the infant undergoing reconstructive tracheal surgery.
In: RECONSTRUCTIVE TRACHEAL SURGERY IN INFANTS, Lobe T, ed, WB Saunders, Philadelphia PA, 1991:125—137
12. Patel J and Snodgrass WR: Pediatric clinical pharmacology of penicillins.
In: PEDIATRIC PHARMACOLOGY, Yaffe SJ and Aranda JV, eds, WB Saunders, Philadelphia PA, 1992:237—243
13. Snodgrass WR: Pediatric Clinical Pharmacology.
In: MELMON AND MORELLI'S CLINICAL PHARMACOLOGY: BASIC PRINCIPLES IN THERAPEUTICS, 3rd ed, Melmon KL et al, eds, McGraw-Hill, NY, 1992:826—850
14. Snodgrass WR: Clinical Toxicology.
In: CASARETT AND DOULL'S TOXICOLOGY: THE BASIC SCIENCE OF POISONS, 5th ed, Klaassen CD, ed, McGraw-Hill, NY, 1996:969—986
15. Klein G and Snodgrass WR: Toxins in foods: contemporary issues.
In: Cambridge History and Culture of Human Nutrition
Cambridge University Press, NY, 1994: 2318—2324 and 3006—3010
16. Klein G and Snodgrass WR: Food toxins and poisons from microorganisms.
In: The Cambridge World History of Food, vol II, Kiple KF and Ornelas KC (eds)
Cambridge University Press, NY, 2000:1694—1703
17. Snodgrass WR: Diagnosis and treatment of poisoning due to pesticides.
In: HANDBOOK OF PESTICIDE TOXICOLOGY, 2nd ed, Krieger RI, ed, Academic Press, NY, 2001:589--602

C. ABSTRACTS

1. Maickel RP and Snodgrass WR: Some aspects of drug placental transfer.
Fourth International Pharmacological Congress, Basel, Switzerland, 1969
2. Maickel RP, McGlynn M and Snodgrass WR: Some toxicological aspects of the chronic administration of phenothiazine tranquilizers.
Toxicol Appl Pharmacol 1970;17:213
3. Bowman DR, Fedynskyj N, Ryan MP, Snodgrass WR and Maickel RP: Strain differences in effects of iproniazid on mouse liver triglycerides.
Pharmacologist 1973;15:261
4. Ryan MP, Snodgrass WR and Maickel RP: Biochemical changes evoked by iproniazid in mice on normal and pyridoxine-deficient diets.
Pharmacologist 1973;15:261

5. Snodgrass WR, Bowman DR, Ryan MP, Seeger J and Maickel RP: Physicochemical disposition of iproniazid in normal and pyridoxine-deficient mice. *Pharmacologist* 1973;15:261
6. Snodgrass WR, Potter WZ, Timbrell JA, Jollow DJ and Mitchell JR: Possible mechanism of isoniazid-related hepatic injury. *Clin Res* 1974;22:323A
7. Nelson SD, Snodgrass WR and Mitchell JR: Metabolic activation of hydrazine to reactive intermediates: mechanistic implications for isoniazid and iproniazid hepatitis. *Fed Proc* 1975;34:784
8. Mitchell JR, Nelson SD, Snodgrass WR and Timbrell JA: Metabolic activation of hydrazines to highly reactive hepatotoxic intermediates. IUPHAR SATELLITE SYMPOSIUM ON ACTIVE INTERMEDIATES: FORMATION, TOXICITY AND INACTIVATION, Turku, Finland, 1975, ISBN 951-780-018-5
9. Snodgrass WR, Rollins D, Franklin RB, Taylor AA and Mitchell JR: Effect of aminogluthethimide treatment on blood pressure in patients with low-renin essential hypertension. Fourth Pharmacology-Toxicology Program Symposium, National Institute of General Medical Sciences, Washington DC, 1975:42
10. McMurtry RJ, Snodgrass WR and Mitchell JR: Metabolic activation of acetaminophen, cephaloridine and other chemically stable compounds to nephrotoxic metabolites. *Clin Res* 1976;24:407A
11. Mitchell JR, Franklin RB, Taylor AA, Snodgrass WR, Gill JR and Bartter FC: Role of sodium-retaining steroids in low renin essential hypertension. *Clin Res* 1976;24:424A
12. Taylor AA, Mitchell JR, Rollins DE, Snodgrass WR and Bartter FC: Effect of spironolactone on adrenal and gonadal steroids in man. *Clin Res* 1976;24:279A
13. Rosen RA, Taylor AA, Mitchell JR, Snodgrass WR, Rollins DE and Bartter FC: Effect of spironolactone on the renin-aldosterone system of patients with normal renin or low renin essential hypertension. *Clin Res* 1976;24:239A
14. Rollins DE, Mitchell JR, Taylor AA, Snodgrass WR, Rosen RA, McMurtry RJ, Gill JR and Bartter FC: Heterogeneity of patients with low renin hypertension diagnosed by renin-sodium index. *Clin Res* 1976;24:238A
15. Taylor AA, Pool J, Rosen R, Snodgrass WR, Rollins DE, McMurtry RJ, Bartter FC and Mitchell JR: Major abnormality in low renin hypertension: exaggerated aldosterone response to angiotensin. *Clin Res* 1977;25:466A
16. Snodgrass WR, Peterson RG and Rumack BH: Tobramycin determination in low birth weight infants by HPLC. *Pediatric Res* 1980;14:472
17. Snodgrass WR, Walker L, Heideman R, Odom L, Hays T and Tubergen D: Kinetics of VP-16 epipodophyllotoxin in children with cancer. *Proc Amer Soc Clin Oncol* 1980;21:33

18. Snodgrass WR and Whitfield S: Possible mechanism of phenytoin liver injury: phenytoin-associated glutathione depletion.
Veterin Human Toxicol 1981;23:32
19. Maickel RP, Seeger J and Snodgrass WR: Tissue localization and covalent binding of 14C-iproniazid in mice: effect of normal and pyridoxine-deficient diet.
Second International Symposium on Radiopharmacology, Chicago IL, 1981
20. Snodgrass WR, Smith SD, Trueworthy R and Vats TS: 6-Mercaptopurine serum levels in children with acute lymphocytic leukemia.
Pediatric Oncology Group (POG), Orlando FL, 1981
21. Snodgrass WR: Phenytoin teratogenic injury in a mouse animal model: possible role of a reactive metabolite.
Pediatr Res 1982;16:131A
22. Snodgrass WR: Early aggressive activated charcoal treatment of elemental yellow phosphorus poisoning.
Veterin Human Toxicol 1982;24:288
23. Snodgrass WR, Smith SD, Trueworthy R and Vats TS: Kinetics of 6-mercaptopurine in children with acute lymphocytic leukemia in remission.
Pediatric Oncology Group (POG), St Louis MO, 1982
24. Snodgrass WR and Whitfield S: Furosemide biotransformation in a premature infant: urinary excretion of furosemide and its glucuronide metabolite.
First International Symposium on Developmental Pharmacology, Toronto, Canada, 1982
25. Rachmel AR and Snodgrass WR: Human neonatal furosemide metabolism: urinary excretion of furosemide and furosemide glucuronide.
Clin Pharmacol Therap 1983;33:246
26. Kemner JM, Snodgrass WR, Worley SE, Hodges GR, Clark GM and Hignite CE: Interaction of oxygen-carrying resuscitation fluids with morphine.
Central Society for Clinical Research Chicago IL, 1983
27. Hodges GR, Reed JS, Hignite CE and Snodgrass WR: Blood substitutes: effects on drug pharmacokinetics.
In: ADVANCES IN BLOOD SUBSTITUTE RESEARCH, Bolin RB et al, eds, Alan Liss Inc, NY, 1983:430
28. Snodgrass WR, Kisker S and Rozman K: Enhanced elimination of an environmental chlorinated hydrocarbon in man: use of oral mineral oil and cholestyramine.
Veterin Human Toxicol 1983;25:59
29. Snodgrass WR, Kisker S and Rozman K: Metabolism and kinetics of chlordane in man after oral mineral oil/cholestyramine treatment.
Proceedings of the First International Symposium on Foreign Compound Metabolism, West Palm Beach FL, 1983
30. Smith SD, Trueworthy RC, Klopovich PM, Vats TS and Snodgrass WR: Testicular leukemia: evidence for temporary drug resistance.
Amer Soc Hematol, 1983

31. Snodgrass WR, Dills R, Kisker S and Whitfield S: Phenytoin teratogenesis: a possible mechanism.
Gordon Conference on Drug Metabolism, New Hampshire, 1983
32. Rachmel A, Hazelton G, Klaassen CD and Snodgrass WR: Glucuronidase resistant forms of furosemide glucuronide: evidence of pH dependent isomerization.
Fed Proc 1984;43:340
33. Snodgrass WR, Smith SD, Trueworthy R, Vats TS, Klopovich P and Kisker S: Pediatric clinical pharmacology of 6-mercaptopurine: lack of compliance as a factor in leukemia relapse.
Proc Amer Soc Clin Oncol 1984;3:204
34. Snodgrass WR, Smith SD, Klopovich PM, Vats TS, Trueworthy RC, Kisker S and Melethil S: Pediatric clinical pharmacology of 6-mercaptopurine: drug disposition variability as a factor in leukemia relapse.
Fed Proc 1984;43:951
35. Snodgrass WR and Nyman D: Increased acetaminophen glutathione metabolite formation in children: role in decreased childhood acetaminophen hepatotoxicity.
Pediatr Res 1984;18:145A
36. Rachmel A and Snodgrass WR: Furosemide glucuronidation in infants: implications of beta-glucuronidase resistant isomer formation.
Pediatr Res 1984;18:159A
37. Snodgrass WR, Linshaw M, Schoenleber M, Wasserman G and Green V: Mobilization of lead (Pb) body stores in asymptomatic children: time course of urinary excretion.
Pharmacologist 1984;26:185
38. Hughes HW, Mamlok RJ, Dodge WF and Snodgrass WR: Metabolic acidosis, hyperglycemia and ketonuria in carbamazepine overdose.
Clin Res 1984;32:881A
39. Snodgrass WR, Smith SD, Trueworthy RC, Vats TS and Melethil S: Probable enterohepatic cycling of 6-mercaptopurine in children.
Clin Pharmacol Therap 1985;37:230
40. Hughes HW, Mamlok RJ, Dodge WF and Snodgrass WR: Metabolic acidosis, hyperglycemia and ketonuria in carbamazepine overdose.
Pediatr Res 1985;19:142A
41. Rachmel A, Snodgrass WR, Klaassen CD and Hazelton GA: Ontogeny of rat liver microsomal UDP-glucuronosyl transferase activity towards furosemide.
Pediatr Res 1985;19:178A
42. Neal MB, Wolf WJ, Nicholas D, Solanki D, Hadrzynski CL and Snodgrass WR: Pharmacokinetics of narcotics in conjoined twins.
Clin Res 1986;34:237A
43. Hadrzynski C, Casta A, James G, Roy D, Dodge WF and Snodgrass WR: Propranolol serum pharmacokinetics in infants under one year of age: inadequate assessment without tracer isotope methodology or prolonged terminal elimination phase sampling.
Pediatr Res 1986;20:204A
44. Hadrzynski CL, Morgan DP, Winsett OP, Roy D and Snodgrass WR: Mobilization of a halogenated hydrocarbon pesticide from body fat in man: lindane.

- Veterin Human Toxicol 1986;28:471
45. Tisdell RH, Ellis M and Snodgrass WR: Methylmercaptan (methanethiol) acute pulmonary edema, coma and death in two oil-field workers.
Veterin Human Toxicol 1986;28:471—472
 46. Marti R, Iacobucci MA and Snodgrass WR: Methemoglobinemia following buccal mucosal absorption of benzocaine.
Veterin Human Toxicol 1986;28:482
 47. Winter ML, Hope WG, Roy D, Leggitt JL, Ellis M and Snodgrass WR: Urine fluorescence using a Wood's lamp to detect the antifreeze additive fluorescein: a qualitative adjunctive test in suspected ethylene glycol ingestions.
Veterin Human Toxicol 1986;28:492
 48. Tisdell RH, Iacobucci MA and Snodgrass WR: Caffeine poisoning in an adult: survival with a serum concentration of 400 mg/l and need for adenosine agonist antidotes.
Veterin Human Toxicol 1986;28:492
 49. Roy D and Snodgrass WR: Role of thiols (protein and nonprotein) in metabolic activation of phenytoin.
Fed Proc 1987;46:1139
 50. Snodgrass WR and Roy D: Shunting of phenytoin in vitro metabolic activation by glutathione to less reactive metabolites: animal and human fetal tissue.
Pediatr Res 1987;21:242A
 51. Esquivel MT, McCormick DP and Snodgrass WR: Hazard from ammonia inhalant ampules in children.
Clin Res 1987;35:55A
 52. Snodgrass WR and Roy D: Phenytoin in vitro metabolic activation and the role of glutathione in human fetal tissue.
Pediatr Res 1988;23:264A
 53. Douidar SM, Dodge WF and Snodgrass WR: Acetaminophen toxic metabolite markers (mercapturic acid and cysteine conjugates) urinary excretion in febrile versus afebrile children. Possible evidence for lack of interferon P-450 blockade.
Veterin Human Toxicol 1988;30:368
 54. Douidar SM, Dodge WF and Snodgrass WR: Acute versus chronic noncompliance: baseline control study in children given sulfisoxazole.
Pediatr Res 1989;25:66A
 55. Mostafa N, Loh JP, Douidar SM, Snodgrass WR, Ahmed EA and Pollard RB: Molecular interaction of recombinant alpha interferon and zidovudine (AZT): alterations of AZT pharmacokinetics in HIV-infected patients.
Fifth International Conference on AIDS, Montreal, Canada, 1989:278
 56. Douidar SM and Snodgrass WR: Fatal iron-dextran poisoning: possible combined iron toxicity and dextran-induced immune block.
Veterin Human Toxicol 1989;31:342
 57. Winter ML, Nelson DA and Snodgrass WR: Industrial exposure to acetone cyanohydrin: delayed onset cyanide toxicity.

- Veterin Human Toxicol 1989;31:354
58. Villalobos D, Ellis MD and Snodgrass WR: Isotretinoin (Accutane)-associated psychosis.
Veterin Human Toxicol 1989;31:362
 59. Marti R, Winter ML and Snodgrass WR: Neurologic sequelae from manganese (Mn) exposure in a child: treatment with carbidopa/levodopa.
Veterin Human Toxicol 1990;31:343
 60. Winter ML and Snodgrass WR: Hydrogen peroxide emesis: a possible alternative if ipecac is not available.
Veterin Human Toxicol 1991;33:352
 61. Thompson JD and Snodgrass WR: Inflatable toys: an unusual source of freon toxicity.
Veterin Human Toxicol 1991;33:363
 62. Winter ML, Haynes JF and Snodgrass WR: Low to moderate hazard from ammonia inhalant ampules.
Veterin Human Toxicol 1991;33:364
 63. Villalobos D and Snodgrass WR: Elevated mercury (Hg) levels from mercury-filled bullets.
Veterin Human Toxicol 1991;33:364
 64. Douidar SM, Dodge WF and Snodgrass WR: Acetylator phenotype in children given sulfisoxazole using a multicompartment pharmacokinetic model.
Clin Pharmacol Therap 1992;51:107
 65. Hammond DK, Goldblum RM, Snodgrass WR and Liehr JG: Development of an immunoassay for caffeine metabolites 5-acetylamino-6-amino-3-methyluracil and 1-methylxanthine.
Biointernational Conference on Technology, Houston TX, 1993
 66. Rosen PB and Snodgrass WR: Utility of a urinary thioether assay as a biomarker.
Society of Occupational and Environmental Health, Chapel Hill NC, 1995
 67. Jenouri GA, Snodgrass W, Shippy A and Morrison RJ: Severe nickel carbonyl pneumonitis: survival with disulfiram chelation.
American Thoracic Society, 1997
 68. Baker SD, Frazer PJ and Snodgrass WR: Occupational nickel carbonyl exposure in a group of workers.
J Toxicol Clin Toxicol 1998;36:497
 69. Lieber BL and Snodgrass WR: Cardiac arrest following a large intravenous fosphenytoin overdose in an infant.
J Toxicol Clin Toxicol 1998;36:473
 70. Snodgrass WR: Environmental toxicology risks in infants and children.
Invited keynote presentation.
European Association of Poison Centers and Clinical Toxicologists
May 2001, Barcelona, Spain
 71. Snodgrass WR: Toxicologic causes, mechanisms, and approaches to treatment of anoxic and chemically-induced brain injury.
Invited keynote presentation.
European Association of Poison Centers and Clinical Toxicologists